Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience (NASDAQ: NAGE) announced that senior leadership will participate in four investor conferences during November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A.G.P. Virtual Consumer Showcase
- Virtual showcase offering consumer company management teams a platform to share their story with the investment community
- Location: Virtual
- Date: November 11 - 12, 2026
- Format: Fireside chat Thursday, November 12, 2026 at 3:00 p.m. ET
- Management: Rob Fried, CEO & Ozan Pamir, CFO
- Investors may register here
Southwest IDEAS Investor Conference
- Independent institutional investor conference for publicly traded companies and institutional investors
-
Location: The Westin Irving Convention Center in Las Colinas,
Irving, Texas - Date: November 18 - 19, 2026
- Format: Presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT and one-on-one meetings
- Management: Rob Fried, CEO & Ozan Pamir, CFO
15th Annual ROTH Deer Valley Event
- Invite-only annual networking conference for institutional investors and select public/private company management teams.
-
Location: Montage Deer Valley
Park City, Utah - Date: December 9 - 12, 2026
- Format: One-on-one meetings
- Management: Rob Fried, CEO
StoneX 15th Annual Discovery Conference 2026
- Emerging growth investor forum for institutional investors and select public and private emerging growth companies.
-
Location: New York Athletic Club
New York, New York - Date: December 10, 2026
- Format: One-on-one meetings
- Management: Ozan Pamir, CFO
If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com.
For additional information on Niagen Bioscience, visit www.niagenbioscience.com.
About Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.
Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.
†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)
View source version on businesswire.com: https://www.businesswire.com/news/home/20261109675021/en/
Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
kendall.knysch@niagenbio.com
Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Niagen@kcsa.com
Source: Niagen Bioscience, Inc